Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01372579
Recruitment Status : Active, not recruiting
First Posted : June 14, 2011
Last Update Posted : July 6, 2017
Eisai Inc.
Information provided by (Responsible Party):
Northwestern University